The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
12/14/2012
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
PA-13-042
Opportunity Category:
Discretionary
Posted Date:
Dec 14, 2012
Creation Date:
Dec 14, 2012
Original Closing Date for Applications:
Mar 13, 2015
Current Closing Date for Applications:
Mar 13, 2015
Archive Date:
Apr 13, 2015
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Health
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
$4,000,000
Award Ceiling:
Award Floor:
CFDA Number(s):
93.855
--
Allergy, Immunology and Transplantation Research
93.856
--
Microbiology and Infectious Diseases Research
Cost Sharing or Matching Requirement:
No
Eligible Applicants
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility:
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Name
National Institutes of Health
Description
The goal of the IPCAVD Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the first 5 years of the award. The reduced support for two additional years will support ongoing stability studies, updating regulatory submissions and further optimization as informed from the clinical studies. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. A clinical development plan describing means to initiate a clinical study during the first 5 years of award is a requirement of this FOA.
